EGFR突变非小细胞肺癌中原发性EGFR拷贝数增加的基因组特征及其对一线EGFR酪氨酸激酶抑制剂疗效的影响
这项多中心回顾性真实世界研究纳入两个队列,采用二代测序检测未经治疗组织标本的EGFR拷贝数增加(CNG)。队列1(355例)显示EGFR CNG对一线EGFR-TKI的无进展生存期和客观缓解率均无显著影响;队列2(7876例)中16.4%存在EGFR CNG,且伴TP53、IKZF1、RAC1、MYC、MET、CDKN2A/B及代谢相关和ERK信号通路改变。结论为原发性EGFR CNG不影响一线EGFR-TKI疗效,但EGFR CNG肿瘤基因组更复杂。
要点
- EGFR CNG组与非CNG组、不确定组一线EGFR-TKI的PFS无显著差异(10.0个月 vs 10.8个月 vs 9.9个月,p=0.384)。
- EGFR CNG组客观缓解率与非CNG组、不确定组比较无统计学显著差异(70.3% vs 63.2% vs 54.5%,p=0.154)。
- 7876例NSCLC患者中16.4%存在EGFR CNG,且伴随更复杂的基因组改变。
核心结论
- 原发性EGFR拷贝数增加对EGFR突变NSCLC患者一线EGFR-TKI疗效无影响。
- 伴有EGFR拷贝数增加的肿瘤比不伴有的肿瘤具有更复杂的基因组图谱。
研究设计与样本
- 多中心、回顾性、真实世界研究,包含两个队列,纳入EGFR突变NSCLC患者。
- EGFR拷贝数增加通过未经治疗组织标本的二代测序检测。
- 队列1检测EGFR拷贝数增加对一线EGFR-TKI治疗的影响,队列2探索基因组特征。
- 队列1于2013年1月至2022年3月从四个癌症中心纳入355例患者。
- 队列2纳入7876例NSCLC患者。
主要发现
- 队列1患者分为EGFR非拷贝数增加组、EGFR拷贝数增加组和EGFR不确定拷贝数增加组。
- 三组间无进展生存期无显著差异(10.0个月 vs 10.8个月 vs 9.9个月,p=0.384)。
- EGFR拷贝数增加组与非拷贝数增加组或不确定组的客观缓解率无统计学显著差异(70.3% vs 63.2% vs 54.5%,p=0.154)。
- 队列2中16.4%的NSCLC患者显示EGFR拷贝数增加。
- 与不伴EGFR拷贝数增加的患者相比,伴EGFR拷贝数增加的患者中TP53、IKZF1、RAC1、MYC、MET、CDKN2A/B等基因突变及代谢相关和ERK信号通路改变显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation generally respond well to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). However, genomic characterisation of de novo EGFR copy number gain (CNG) and its impact on the efficacy of first-line EGFR-TKIs remains unclear. METHODS: This multicenter, retrospective and real-world study included two cohorts that enroled EGFR mutant NSCLC patients. EGFR CNG was tested by next-generation sequencing of untreated tissue specimens. Cohort 1 detected the impact of EGFR CNG on first-line EGFR-TKIs treatment, and cohort 2 explored the genomic characterisation. RESULTS: Cohort 1 enroled 355 patients from four cancer centres between January 2013 and March 2022. The patients were divided into three groups, included the EGFR non-CNG, EGFR CNG, and EGFR uncertain-CNG. No significant difference in progression-free survival (PFS) was found between the three groups (10.0 months vs. 10.8 months vs. 9.9 months, respectively, p = 0.384). Furthermore, the overall response rate was not statistically significant in the EGFR CNG group compared to the EGFR non-CNG or uncertain arm (70.3% vs. 63.2% vs. 54.5%, respectively, p = 0.154). Cohort 2 included 7876 NSCLC patients with 16.4% showing EGFR CNG. Gene mutations such as TP53, IKZF1, RAC1, MYC, MET, CDKN2A/B and alterations of the metabolic-related and ERK signalling pathway were significantly associated with patients with EGFR CNG compared to those without. CONCLUSIONS: De novo EGFR CNG had no effect on the efficacy of first-line EGFR-TKI treatment in EGFR mutant NSCLC patients, and tumours with EGFR CNG had more complex genomic profiles than those without.
引用
- Xu Y, Yan J, Zhou C, et al. Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer. Eur J Cancer. 2023. PMID: 37201385. doi:10.1016/j.ejca.2023.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。